ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Segelov, Eva ^a   Waring, Paul ^b   Desai, Jayesh ^c,d   Wilson, Kate ^e   Gebski, Val ^e   Thavaneswaran, Subotheni ^e   Elez, Elena ^f   Underhill, Craig ^g   Pavlakis, Nick ^e   Chantrill, Lorraine ^h,i   Nott, Louise ^j   Jefford, Michael ^d   Khasraw, Mustafa ^e,k   Day, Fiona ^l   Wasan, Harpreet ^m   Ciardiello, Fortunato ⁿ   Karapetis, Chris ^o   Joubert, Warren ^p   Hazel, Guy ^q   Haydon, Andrew ^r   Price, Tim ^s   Tejpar, Sabine ^t   Tebbutt, Niall ^u   Shapiro, Jeremy ^v   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g Border Medical Oncology Australia   (Australia)

^h CAMPBELLTOWN HOSPITAL   (Australia)

ⁱ GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^j ROYAL HOBART HOSPITAL   (Australia)

^k Andrew Love Cancer Centre   (Australia)

^l UNIVERSITY OF NEWCASTLE   (Australia)

^m HAMMERSMITH HOSPITAL   (United Kingdom)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o FLINDERS MEDICAL CENTRE   (Australia)

^p PRINCESS ALEXANDRA HOSPITAL   (Australia)

^q SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^r ALFRED HOSPITAL   (Australia)

^s QUEEN ELIZABETH HOSPITAL   (Australia)

^t UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^u AUSTIN HOSPITAL   (Australia)

^v CABRINI HOSPITAL   (Australia)

more..

Author keywords

Cetuximab; Clinical trial; Colorectal tumours; Irinotecan; Tumour mutations

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; TUMOR MARKER; ANTINEOPLASTIC AGENT; ATF6B PROTEIN, HUMAN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21;

ADULT; ARTICLE; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CODON; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; G13D GENE; GENE; GENE MUTATION; HEALTH CARE COST; HUMAN; HUMAN TISSUE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY; NRAS GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PI3KCA GENE; PREDICTION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WILD TYPE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; METHODOLOGY; MUTATION;

ANTINEOPLASTIC AGENTS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CAMPTOTHECIN; CETUXIMAB; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GTP PHOSPHOHYDROLASES; HUMANS; MEMBRANE PROTEINS; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RESEARCH DESIGN;

EID: 84971576958     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2389-8     Document Type: Article

References (20)

1. Cunningham D et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New Engl J Med. 2004;351:337-45.
2. Van Cutsem E et al. Open-label phase III trial of panitumumab plus best supportiive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64.
3. Siu L et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol. 2013;31:2477-84.
4. Karapetis C et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New Engl J Med. 2008;359:1757-65.
5. Amado R et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
6. Oliner K, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment for metastatic colorectal cancer. J Clin Oncol, 2013;31(15_suppl 3511).
7. Ciardiello F, et al. Treatment outcome according to tumor RAS mutational status in CRYSTAL study patients with metastatic colorectal cancer randomized to FOLFIRI with/without cetuximab. J Clin Oncol. 2014;32 suppl abstract 3506.
8. Schirripa M et al. Role of NRAS muations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136:83-90.
9. Tian S et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62(4):540-9.
10. De Roock W et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;304:753-62.
11. De Roock W et al. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA. 2010;304(16):1812-20.
12. Tejpar S, et al. Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer treated with first line chemotherapy with or without cetuximab. J Clin Oncol3 2011;29 suppl abstr 3511.
13. Mao C et al. KRASp.G13D Mutation and Codon 12 Mutations AreNot Created Equal in Predicting Clinical Outcomes of Cetuximab in Metastatic Colorectal Cancer. Cancer. 2012;19:714-21.
14. Peeters M et al. Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab. J Clin Oncol. 2013;31:759-65.
15. De Roock W et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-15.
16. Piessevaux H et al. Radiological tumor size decreases at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol. 2009;20:1375-82.
17. Piessevaux H et al. Use of Early Tumor Shrinkage to Predict Long-term Outcome in Metastatic Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2013;31:3764-75.
18. Eisenhauer E et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
19. Clark T, Altman D, De Stavola B. Quantification of the completeness of follow-up. Lancet. 2002;359:1309-10.
20. Morelli M, Kopetz S. Hurdles and Complexities of Codon 13 KRAS Mutations. J Clin Oncol. 2012;30:3565-7.